Corcept TherapeuticsCORT
CORT
About: Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Employees: 500
0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
176% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 29
14% more funds holding
Funds holding: 317 [Q3] → 362 (+45) [Q4]
5% more capital invested
Capital invested by funds: $4.03B [Q3] → $4.24B (+$211M) [Q4]
3% less repeat investments, than reductions
Existing positions increased: 116 | Existing positions reduced: 120
3.02% less ownership
Funds ownership: 83.4% [Q3] → 80.38% (-3.02%) [Q4]
21% less call options, than puts
Call options by funds: $58.4M | Put options by funds: $73.7M
29% less funds holding in top 10
Funds holding in top 10: 7 [Q3] → 5 (-2) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$131
110%
upside
Avg. target
$143
130%
upside
High target
$150
141%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Piper Sandler David Amsellem 44% 1-year accuracy 14 / 32 met price target | 110%upside $131 | Overweight Maintained | 3 Apr 2025 |
Canaccord Genuity Edward Nash 58% 1-year accuracy 11 / 19 met price target | 128%upside $142 | Buy Maintained | 1 Apr 2025 |
Truist Securities Joon Lee 41% 1-year accuracy 17 / 41 met price target | 141%upside $150 | Buy Maintained | 31 Mar 2025 |
HC Wainwright & Co. Swayampakula Ramakanth 23% 1-year accuracy 44 / 192 met price target | 141%upside $150 | Buy Maintained | 31 Mar 2025 |
Financial journalist opinion
Based on 23 articles about CORT published over the past 30 days
Positive
Seeking Alpha
2 days ago
It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder
Corcept is transitioning from a single-product company to a multi-product, multi-market Platform Growth™ company, promising rapid revenue and earnings growth. Relacorilant's success in platinum-resistant ovarian cancer and potential FDA approval for hypercortisolism could significantly boost Corcept's market presence and revenue. Corcept's expanding pipeline includes promising treatments for prostate cancer, ALS, MASH, and resistant hypertension, diversifying its product portfolio and reducing investor risk.
Negative
MarketBeat
1 week ago
3 Biopharmaceutical Stocks Bucking the Sell-Off
With tariffs sending markets reeling in the first days of the second quarter—the S&P 500 dropped roughly 10% in the five trading periods through Apr. 7, 2025—investors with cash to spend might be looking for an opportunity. While it's true that some of the biggest firms in the world started April with major share price discounts, investors may want to find companies to target that have been more or less bulletproof in the extreme uncertainty characterizing the market.
Neutral
Business Wire
1 week ago
Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the start of BELLA, a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating efficacy and safety in patients with platinum-resistant ovarian cancer. BELLA is a.
Positive
Zacks Investment Research
2 weeks ago
Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Seeking Alpha
2 weeks ago
Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release
Corcept Therapeutics Incorporated's relacorilant met the primary endpoint in the phase 3 ROSELLA study for platinum-resistant ovarian cancer patients, boosting shares by over 90% the very same day. Upcoming catalysts include full trial data release at a medical conference, NDA filing in Q3 2025, and MAA submission to the EMA shortly afterward. Relacorilant also targets hypercortisolism with endogenous Cushing's Syndrome patients with an FDA PDUFA date set for December 30, 2025, based on positive GRACE, GRADIENT, and phase 2 study data.
Positive
Zacks Investment Research
2 weeks ago
CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal
The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian cancer meets the primary endpoint.
Positive
Zacks Investment Research
2 weeks ago
Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar?
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Positive
Zacks Investment Research
2 weeks ago
Here's Why Momentum in Corcept (CORT) Should Keep going
Corcept (CORT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Positive
Seeking Alpha
2 weeks ago
Corcept Therapeutics: The ROSELLA Trial Presents A Major Win For The Company
Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal, showing promise for relacorilant in treating platinum-resistant ovarian cancer. The ROSELLA trial demonstrated a median progression-free survival of 6.5 months and a significant overall survival gain of 4.5 months with relacorilant. Relacorilant's lack of new safety issues and potential for wide use, combined with promising survival data, suggest strong market potential and likely FDA approval by 2026.
Positive
Benzinga
2 weeks ago
Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast
Corcept Therapeutics Incorporated CORT announced on Monday that the ROSELLA Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer met its primary endpoint of improved progression-free survival, as assessed by blinded independent central review (PFS-BICR).
Charts implemented using Lightweight Charts™